OBN BioTuesday: A spotlight on the latest R&D for Neurodegenerative Diseases

We are pleased to announce details of our next BioTuesday on 17 October, hosted by Ipsen on Milton Park, that will be spotlighting the latest R&D for Neurodegenerative Diseases.


Neurodegenerative disease impacts almost 50 million people globally, and during the past decades, there has been a surge in research interest, funding, and clinical trials to support the development of treatments for the most prevalent neurodegenerative diseases including Alzheimer's and Parkinson's. 


2022 was an important landmark in Alzheimer's disease with FDA approvals for two amyloid immunotherapies, Aducanumab and Lecanemab, but despite this progress, therapies to prevent or decrease disease progression and restore neuronal function remain a challenge and an ongoing focus in both research and clinical practice.


This edition of our BioTuesday event aims to shine a light on the most recent R&D in both diagnostics and treatment of a range of neurodegenerative diseases and will feature an academic update along with presentations from some of the most exciting companies working in this space from the Oxfordshire region.




18.00 – 18.30   Guest arrivals and networking

18.30 – 19.00  Welcome from Ipsen, and Keynote presentation from Brent Ryan,  Research Lecturer, Department of Physiology, Anatomy & Genetics, University of Oxford

19.00 - 20.00   R&D Showcase Presentations:

Peter Hamley, CSO, Samsara Therapeutics

Francesca Cordeiro, Founder and Director, Novai

Fraser Murray, CEO, Pheno Therapeutics

Gilles Ouvry, VP of Chemistry, NRG Therapeutics

Baroness Susan Greenfield CBE. CEO and Founder, Neuro-Bio

20.00 - 20.30  Audience & Presenter Q&A

20.30 – 21.30   Networking


  • Brent Ryan (Departmental Research Lecturer at Department of Physiology, Anatomy & Genetics (DPAG))

    Brent Ryan

    Departmental Research Lecturer at Department of Physiology, Anatomy & Genetics (DPAG)


    Following from my undergraduate and PhD at Exeter University I joined the University of Oxford in 2010 and have worked as part of the Oxford Parkinson’s Disease Centre to understand Parkinson’s.
    My Laboratory is focussed on using high-throughput biology and ‘Omics approaches to investigate the biology underpinning mitochondrial and lysosomal dysfunction in neurodegeneration. We work closely with industrial and academic collaborators and has established high-throughput phenotypic screening platforms, using CRISPRi or compounds, in mature patient iPSC-derived neurons, primary rodent neurons and cell lines to identify novel targets and drugs, some of which are currently being progressed into animal models.

    view more
  • Fraser Murray (CEO of Pheno Therapeutics)

    Fraser Murray

    CEO of Pheno Therapeutics


    Dr Fraser Murray is an experienced drug hunter and entrepreneur with almost 30 years of experience in drug discovery and early development in both pharma and biotech. In addition to being CEO of Pheno Therapeutics he is currently Head of Scientific Evaluation at Advent Life Sciences. He was most recently Chief Executive Officer of Pandeia Therapeutics which was acquired by a mid-cap pharmaceutical company in December 2022.

    view more
  • Francesca Cordeiro (Founder and Director of Novai)

    Francesca Cordeiro

    Founder and Director of Novai


    Professor M Francesca Cordeiro, is a clinician-scientist, Chair of Ophthalmology Imperial College London, and UCL Professor, Honorary Consultant Ophthalmologist/Research Lead, Director of the ICORG Clinical Trials Unit at the Western Eye Hospital London, and recently Founder and Director of Novai Ltd, a start-up company based on DARC Technology.

    Her research, funded continuously by the Wellcome Trust since 1996, focuses on novel and translational approaches with a target of saving sight and reducing disability, with over 180 peer-reviewed publications.

    She has received a number of international awards for this work, including the Lewis Rudin Glaucoma Prize 2005, the Research to Prevent Blindness International Research Scholar Award 2015, the GG2 Diversity Award for Outstanding Achievement in Medicine 2017 and 2019 Duke Elder Award (Royal College of Ophthalmologists) and is frequently asked to give keynote lectures abroad.

    view more
  • Gilles Ouvry (VP of Chemistry at NRG Therapeutics Ltd)

    Gilles Ouvry

    VP of Chemistry at NRG Therapeutics Ltd


    Currently VP of chemistry at NRG Therapeutics, Gilles Ouvry has over 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS. His experience spans from lead generation through to successful clinical candidate selection. During his career he has worked on over 20 drug discovery projects, managing internal and outsourced teams, and leading or participating in the discovery of multiple pre-clinical development candidates and four compounds that have progressed into clinical trials. He has a degree and PhD in organic chemistry from Ecole Polytechnique, Palaiseau, France.

    view more
  • Peter Hamley (Chief Scientific Officer at Samsara Therapeutics Ltd)

    Peter Hamley

    Chief Scientific Officer at Samsara Therapeutics Ltd


    Peter is CSO of Samsara Therapeutics, an Oxford-based biotech company with a focus on autophagy and neurodegeneration. He spent more than a decade at Sanofi, in various global discovery and business development roles. He and his teams have contributed to the advancement of many projects into development across multiple therapeutic areas. He started his career at AstraZeneca after postdoctoral studies at the University of Pennsylvania, a PhD from Cambridge University, and a BSc in Chemistry from Imperial College London. He holds an MBA from the University of Bath.

    view more
  • Baroness Susan Greenfield CBE (CEO & Founder of Neuro-Bio Ltd)

    Baroness Susan Greenfield CBE

    CEO & Founder of Neuro-Bio Ltd


    Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist and has published over 200 papers in peer-reviewed journals over the course of her 40-year career, based mainly at Oxford University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.

    view more



102 Park Dr, Milton, Abingdon OX14 4RZ
England, United Kingdom

If you have any questions please contact

Contact Organizer

Show on map


OBN Member - Complimentary Ticket
Member Price Complimentary
Non-OBN Member Ticket
Standard Price £50
Academic & Research Scientists Complimentary
Standard Price Complimentary
Speaker (Sold Out)
Standard Price Complimentary